IES61567B2 - Pharmaceutical products - Google Patents

Pharmaceutical products

Info

Publication number
IES61567B2
IES61567B2 IES940272A IES61567B2 IE S61567 B2 IES61567 B2 IE S61567B2 IE S940272 A IES940272 A IE S940272A IE S61567 B2 IES61567 B2 IE S61567B2
Authority
IE
Ireland
Prior art keywords
sotalol
class
antiarrhythmic drug
class iii
atenolol
Prior art date
Application number
Inventor
Helmut Schickaneder
Original Assignee
Russinsky Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Russinsky Ltd filed Critical Russinsky Ltd
Priority to IES940272 priority Critical patent/IES61567B2/en
Priority to IE940544A priority patent/IE73656B1/en
Priority to GB9413859A priority patent/GB2286529B/en
Priority to BE9400639A priority patent/BE1006859A6/en
Publication of IES940272A2 publication Critical patent/IES940272A2/en
Publication of IES61567B2 publication Critical patent/IES61567B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A combination product of a class III Antiarrhythmic drug, especially (+)-Sotalol.HCl, and a class II Antiarrhythmic drug, e.g. (+/-)-Sotalol.HCl is useful for cardioprotective effects. The product may be in an oral dosage form in a weight ratio of approximately 9 parts +)-Sotalol to 1 part (+/-)-Sotalol.

Description

The invention relates to pharmaceutical combination products, processes for their preparation and their use as medicaments .
As outlined, for example, in US 5,089,526 Antiarrhythmic drugs are commonly divided into four classes according to their electrophysical mode of action. The classifications are: I Local Anaesthetic effect II Beta-receptor blockage III Prolongation of action potential duration IV Calcium antagonism.
Class I agents generally exert local anaesthetic activity directly at a cardiac cell membrane but have little or no action potential duration (APD).
Class II agents exert their effects through competitive inhibition of beta-adrenergic receptor sites thereby reducing sympathetic excitation of the heart. They generally have little or no effect on action potential duration (APD).
The characteristic of Class III agents is their ability to prevent or ameliorate arrhythmias by lengthening the action potential duration (APD).
US 5,089,526 describes (+)-Sotalol as a Class III Antiarrhythmic drug as it lengthens the action potential duration of cardiac cells and is thereby useful in treating heart arrhythmias . ·> 25 (+)-Sotalol-HCl may be represented by the formula: (6 ch3 CH-CH,-NH-CH ,.HCI i J CH CH3 According to the invention there is provided a combination product of a class III Antiarrhythmic drug with a class II Antiarrhythmic drug.
In a particularv preferred embodiment of the invention the class III Antiarrhythmic drug comprises a pharmaceutically acceptable salt of (+)-Sotalol, especially ( + )Sotalol,HC1.
In an especially preferred arrangement the class II Antiarrhythmic drug is selected from one or more of:propranolol, oxprenolol, practolol, pindolol, metindol, nadolol, labetalol, acebutolol, bisoprolol, bunitrolol, tolamolol, formoterol, celiprolol, bupranolol, (i)-Sotalol, (±)-Atenolol, (-)-Atenolol, (+)-Metoprolol, (-)-Metoprolol, and pharmaceutically acceptable salts, diastereoisomers as racemates or as enantiomers or mixture of diastereoisomers thereof.
Typically the class II Antiarrhythmic drug comprises a pharmaceutically acceptable salt of (i) Sotalol, < especially ( + ) Sotalol HC1.
Preferably the product is in oral dosage form, typically in a capsule or tablet form.
In one embodiment of the invention the weight ratio of the ? class III Ant iar rhythmic drug to the class II Antiarrhythmic drug is from 99:1 to 60:40.
In a preferred arrangement the class III Antiarrhythmic 5 drug is (+)-Sotalol, the class II Antiarrhythmic drug is (+)-Sotalol, and the weight ratio is approximately 9:1.
The invention also provides in another aspect a pharmaceutical composition comprising (+)-Sotalol HC1 and (±)-Sotalol HC1. In this case preferably the weight ratio 10 of (+)-Sotalol HC1 to (+)-Sotalol HC1 is approximately 9:1.
In a further aspect the invention provides a use of a composition comprising a class III Antiarrhythmic drug and a class II Antiarrhythmic drug for the manufacture of a 15 medicament for cardioprotective effects including for the treatment or prevention of arrhythmias, in the setting of myocardial ischemia in the post infarcted heart and for the treatment of coronary heart disease.
The invention will be more clearly understood from the 20 following description thereof given by way of example only.
The antiarrhythmic activity of the racemate Sotalol and especially of the enantiomeric pure (+)-Sotalol are documented in Arznein Forsch/Drug Res. 38 (I), Nr. 2 (1988) and in US Patent 3,341,584.
Antiarrhythmic drug therapy is the most common approach to 8 arrhythmic suppression. The two usual indications for antiarrhythmic drugs are the relief of symptoms caused by arrhythmia with the potential of sudden cardiac death.
The antiarrhythmic efficiency of class III antiarrhythmic agent, Sotalol, has been related to its prolongation of the cardiac action potential duration (APD)= Control of cardiac arrhythmias by selectively lengthening repolarization has thereby been established as a growing concept in cardiac electrophysiology, and class III antiarrhythmic agents, amiodarone and sotalol, have been in clinical use since 1962 and 1974, respectively.
Racemic Sotalol, a class III antiarrhythmic agent with Badrenergic blocking activity, and its isomer (+)-Sotalol which exerts relatively little but sometimes desired Badrenergic blocking activity, have been shown to produce an equivalent prolongation of APD.
B-blockers are compounds which influence specific Badrenergic-receptors, which have to be blocked in the case of severe heart attacks. Such compounds as well as their activity are recorded in a large number of publications and patent applications.
Since the two groups of compounds act on different blood pressure-regulation systems, in combined use the effect of one definite and clearly described combination partner is raised by the other partner. In combined use this leads to a reduction in the dose of the combination partners, compared with single use as well as a reduction of adverse and undesired side reactions.
Thus the appearance of side effects known for the two classes of substance can be reduced or avoided if there is definite and very well defined combination of the two active compounds .
The following compounds or their physiologically acceptable salts can be considered as β-blockers: Propranolol, oxprenolol, practolol, pindolol, metindol, nadolol, labetalol, bunitrolol, tolamolol, formoterol, acebutolol, bisoprolol, celiprolol, bupranolol, (±)-Sotalol, (±)-Atenolol, (-) Atenolol, (±)-Metoprolol, (-)-Metoprolol In the compounds which possess several chiral atoms all possible diastereoisomers as racemates or as enantiomers, 10 or mixture of various diastereoisomers can be considered.
Particularly preferred as β-blockers are the following; (-)-Atenolol, (i)-Sotalol, (+)-Metoprolol, (+)-Atenolol, (-)-Metoprolol 15 The synthesis of Patent Specificat pure (+)-sotalol ion No. 5,089,526. is described in US The separation of the racemate of the β-blockers are very well described in the literature.
The invention also relates quite generally to products which contain: a) ( + )-sotalol of the formula I or its physiologically acceptable salts and b) a β-blocker or its physiologically acceptable salts as a combination preparation for simultaneous, separate or periodic regulated use antiarrhythmias . in the treatment of The pharmaceutical compositions can be prepared for example, by initially mixing the single components as powders, or by dissolving the single components in a suitable solvent such as, for example, a lower alcohol and then removing the solvent. ς The ratio of the active agents in the combinations and compositions according to the invention is preferably 6099% by weight of (i-)-sotalol to 40-1% by weight of Bblocker.
As mentioned above the compositions and the definite combinations according to the invention can be used in drug therapy, particularly for cardioprotective effects. It is very well known that cardioprotection plays an important part in the antiarrhvthmic activity.
The described combinations may be useful in preventing life-threatening arrhythmias in the setting of myocardial ischemia in the post-infarcted heart as well as for the treatment of coronary heart disease.
The compositions and combinations according to the invention can be orally or parenterally administered in a corresponding pharmaceutical composition. For oral use,, the active compounds are mixed with the additives usual for this purpose such as carriers, stabilizers or inert diluents, and converted by the usual methods into suitable forms for administration, such as tablets, dragees, cylindrical capsules, aqueous, alcoholic or oily suspensions or oily solutions.
An inert carrier e.g. gum arabic, magnesium carbonate, potassium phosphate, lactose, glucose, or starch, particularly maize starch, can be used. In this case, the composition can be formed both as dry or moist granules. * Vegetable and animal oils, such as sunflower oil or cod liver oil for example, can be considered as oily carriers or solvents .
For subcutaneous or i.v. administration, the active substances or their physiologically acceptable salts are brought into solution, suspension or emulsion, optionally with the usually employed substances such as solubilizers, emulsifiers or other auxiliaries.
As solvents for the active combinations and the corresponding physiologically acceptable salts can be considered e.g. water, physiologically salt solutions or alcohols, besides also sugar solutions or also a mixture of the various solvents mentioned.
The salts of the mentioned compounds that can be considered are those, depending on the basic nature of these compounds, with physiologically acceptable inorganic or organic acids such as e.g. HC1, HBr, H2SO4, maleic acid, fumaric acid, succinic acid, tartaric acid and citric acid.
The following example serves to illustrate the present invention, without restricting it thereto; EXAMPLE 1 Preparation of e.n oral combination product from ( + ) Sotalol and (+) .Sotalol. 1000 tablets which contain 90 mg (+)-Sotalol.HC1 and 10 mg of ( + ) Sotalol HC1 are prepared as follows: Dry granules (+)-Sotalol HC1 90g (+) Sotalol HC1 lOg maize starch 12.5g microcrystalline cellulose 2g magnesium stearate 1.
The two active agents are mixed and ground to granules. Microcrystalline cellulose and magnesium stearate are mixed with the granules. The granules so obtained are compressed into 1000 tablets, each tablet containing 90 mg of + Sotalol and 10 mg of ( + ) Sotalol.
Example 2 Beta receptor blocking properties of mixtures of (+) and (+) Sotalol Methods s Experiments were carried out on isolated rat right atria suspended in an organ bath containing Krebs Hensleit solution at 31°C. Contractions were measured using a Grass strain gauge, the signal from which was used to drive a cardiotachometer.
Isoprenaline dose response curves relating the concentration of isoprenaline to the increase in heart rate (HR) were obtained in the absence and presence of 4 mixtures of the isomers of sotalol:- (%D/L) 100/0, 95/5, 75/25, 50/50, at micromolar concentrations of 1.6, 6.4, 15, 64, and 160. The isoprenaline dose response curves were normalised and dose ratio shifts calculated (DR) . Schild plots relating log DR-1 to the concentration of sotalol were constructed and analysed by linear regression.
Results : (1) Control isoprenaline dose response curves.
In the absence of sotalol the baseline heart rate was 175.1 ±2,3 beats/min (mean ± SEM) . The maximum HR brought about by isoprenaline was 316.9 ±3.8 beats/min, and increase of 141.814.8 beats/min. The ED50 for this effect of isoprenaline was 0.97 nano g/ml (95% Cl 1.2-0.8). (2) Effects of sotalol on baseline heart rate and maximum response to isoprenaline.
Both 100%D and and 50/50% D/L sotalol caused similar reductions in the baseline and maximum heart rate response to isoprenaline. Thus the actual change in the heart rate in response to isoprenaline was unaltered:- %DL Baseline HR control 175.1+2.3 100/0 155.012.5 50/50 151.315.4 Max HR Increase HR 316.913.8 141.814.8 302.2110.9 147.219.6 302.3111.5 151.019.0 (3) Effects of sotalol on ED50 of isoprenaline dose response curves .
Dose ratio shifts (DR-1) of isoprenaline dose response curves brought about by mixtures of the isomers of sotalol (%D/L) at the concentrations indicated, (n) number of observations:- 1.6 [sotalol] micromolar 6.4 16.0 64.0 160.0 %D/L 100/0 — 6.2(1) 7.9(4) 15.5(1) 30.3(7) 95/5 5.3(2) 19.6(2) — 71.0(4) 75/25 2.4(1) 9.3(1) 10.9(1) 25.0(1) 23.0(4) 50/50 7.2(2) — 21.0(5) — 143.0(5) Regression analysis of the Schild plot (logDR1/[sotalol]M) for each mixture gave slopes of less than unity, indicating effects of sotalol other than simple competitive inhibition of isoprenaline at the beta adrenceptor. The data for 100%D sotalol gave a slope of 0.56+-0.05 (R=0.96) and for 50/50% D/L sotalol 0.69 +- 0.6 (R=0.96). Thus the slope of the 100%D was significantly less than that of 50/50%D/L. The slopes of the 95/5% and 75/25% D/L mixtures were intermediate between the above two values. The above differences in slope preclude statistical comparison of the elevations of the regression lines. However sufficient data is available at sotalol concentrations of 16 and 160 micromolar to allow the conclusion that, firstly the 100% D-isomer has significant beta-adrenoceptor antagonism and secondly that addition of increasing amounts of L-isomer increase the betaadrenoceptor antagonist effect.
These results show that the effects of the mixture of the isomers of sotalol on heart rate and the response of heart rate to isoprenaline cannot be explained by simple competitive inhibition of isoprenaline at the betaadrenoceptor, since the slopes of the Schild plots are significantly less than unity. Furthermore this reduction 5 in slope is dependent upon the amount of D-isomer present in the mixture and indicates an action of the D-isomer which, despite having beta blocking activity, offsets the beta blocking effects of the L-isomer. Thus mixtures of the two isomers have pharmacological properties which 10 cannot be predicted from the previously known pharmacology of each isomer (eg Singh et al 1987).
The treatment of cardiac arrhythmias in patients with ischaemic heart disease especially when accompanied by the signs and symptoms of heart failure presents a difficult 15 clinical problem, since most anti-arrhythmic drugs, including beta blockers, depress cardiac contractility and may worsen heart failure. However treatment of heart failure with low dose beta-blockers is thought to cause up regulation of cardiac beta adrenoceptors and improve 20 cardiac contractility. Thus a mixture of the isomers of sotalol in which the proportion of L-isomer (which is predominantly a beta blocking isomer) is significantly less than that of the D-isomer (predominantly an antiarrhythmic isomer) will be of use in the treatment of 25 arrhythmias in patients with ischaemic heart disease and/or heart failure.
The invention is not limited to the embodiments hereinbefore described which may be varied in detail. 1. A combination pharmaceutical product or pharmaceutical composition of a class III Antiarrhythmic drug, especially (+)- Sotalol and pharmaceutically acceptable salts thereof with a class II Antiarrhythmic drug selected from one or more of:-

Claims (5)

1. CLAIMS propranolol, oxprenolol, practolol, pindolol, metindol, nadolol, labetalol, bunitrolol, tolamolol, formoterol, acebutolol, bisoprolol, celiprolol, bupranolol, (±)-Sotalol, (±)-Atenolol, (-)-Atenolol, (±)-Metoprolol, (-)-Metoprolol, and pharmaceutically acceptable salts, diastereoisomers as racemates or as enantiomers or mixture of diastereoisomers thereof.
2. A combination product as claimed in claim 2 wherein the class II Antiarrhythmic drug comprises (+)Sotalol.HCl.
3. A combination product as claimed in any preceding claim in an oral dosage form, preferably the weight ratio of the class III Antiarrhythmic drug to the class II Antiarrhythmic drug is from 99:1 to 60:40, most preferably the class III Antiarrhythmic drug is (+)-Sotalol, the class II Antiarrhythmic drug is (±)-Sotalol, and the weight ratio is approximately 9:1.
4. Use of a composition comprising a class III Antiarrhythmic drug and a class II Antiarrhythmic drug for the manufacture of a medicament for cardioprotective effects including for the treatment or prevention of * arrhythmias, in the setting of myocardial ischemia in the post infarcted heart and for the treatment of coronary · heart disease, preferably the class III Antiarrhythmic drug comprises (+)-Sotalol or a pharmaceutically acceptable salt thereof, especially (+)-Sotalol.HC1, preferably the class II Antiarrhythmic drug is selected from one or more ofs10 propranolol, oxprenolol, practolol, acebutolol, pindolol, metindol, nadolol, labetalol, bisoprolol, bunitrolol, tolamolol, formoterol, celiprolol, bupranolol, (+)-Sotalol, (i)-Atenolol, (-)-Atenolol, (+)-Metoprolol, (-)-Metoprolol, and pharmaceutically acceptable salts, diastereoisomers as racemates or as enantiomers or mixture of diastereoisomers thereof, most preferably (±)Sotalol or a pharmaceutically acceptable salt thereof, especially ( + ) Sotalol.HC1, preferably the weight ratio of the class III Antiarrhythmic drug to the class II Antiarrhythmic drug is from 99 si to 60?40, most preferably the class III Antiarrhythmic drug is (+)-Sotalol, the class II Antiarrhythmic drug is (i)-Sotalol, and the weight ratio is approximately 9 s1.
5. A combination product, a pharmaceutical 20 composition or a use substantially as hereinbefore described with reference to the examples.
IES940272 1994-02-17 1994-03-29 Pharmaceutical products IES61567B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IES940272 IES61567B2 (en) 1994-02-17 1994-03-29 Pharmaceutical products
IE940544A IE73656B1 (en) 1994-02-17 1994-07-04 Pharmaceutical products
GB9413859A GB2286529B (en) 1994-02-17 1994-07-08 Combinations of class III antiarrhythmic drug (+)-Sotalol and class II antiarrhythmic drugs
BE9400639A BE1006859A6 (en) 1994-02-17 1994-07-08 Pharmaceutical products.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE940146 1994-02-17
IES940272 IES61567B2 (en) 1994-02-17 1994-03-29 Pharmaceutical products

Publications (2)

Publication Number Publication Date
IES940272A2 IES940272A2 (en) 1994-11-16
IES61567B2 true IES61567B2 (en) 1994-11-16

Family

ID=26319692

Family Applications (1)

Application Number Title Priority Date Filing Date
IES940272 IES61567B2 (en) 1994-02-17 1994-03-29 Pharmaceutical products

Country Status (3)

Country Link
BE (1) BE1006859A6 (en)
GB (1) GB2286529B (en)
IE (1) IES61567B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188162B (en) * 1999-02-05 2002-08-31 Torrent Pharmaceuticals Ltd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089526A (en) * 1983-05-23 1992-02-18 Bristol-Myers Company Antiarrhythmic class III process

Also Published As

Publication number Publication date
IES940272A2 (en) 1994-11-16
BE1006859A6 (en) 1995-01-10
GB9413859D0 (en) 1994-08-24
GB2286529A (en) 1995-08-23
GB2286529B (en) 1998-02-18

Similar Documents

Publication Publication Date Title
AU761521C (en) Pharmaceutical composition comprising a combination of dextro- and laevo- isomers of sotalol
US6884792B2 (en) Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
NO137500B (en) ANALOGICAL PROCEDURE FOR THE PREPARATION OF 2-AMINO-2`, 6`-PROPION-XYLIDIDE FOR USE AS A MEDICINE FOR HEART ARRYTHMIA
US4831054A (en) 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
US5985933A (en) Methods for treating central and peripheral nerve pain
IES61567B2 (en) Pharmaceutical products
IE73656B1 (en) Pharmaceutical products
AU643487B2 (en) Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders
JPH09169755A (en) Amidinohydrazones of ketones obtained from benzo [b] furan, methods for producing them, and medicaments containing these compounds
CH624659A5 (en)
DE2522218B2 (en) Composition for human or veterinary medicine, methylamine derivatives and processes for their preparation
US4173583A (en) Diastereoisomers of 5-(1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
US4146628A (en) Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds
CH667388A5 (en) PHARMACEUTICAL PREPARATIONS CONTAINING 3-AMINOPROPOXY-INDOLE, OR 3-AMINOPROPOXY INDOLES AND DIURETICS, USE OF THE ACTIVE INGREDIENTS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS.
JP4613496B2 (en) Arrhythmia treatment
Seedat Treatment of hypertension with the aid of beta-adrenergic blocking drugs
EP1670551A1 (en) Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias
WO2021261598A1 (en) Therapeutic agent for drug-induced bradycardia and bradyarrhythmia
DE3602304A1 (en) Pharmaceutical formulations containing 3-aminopropoxyindoles which are optionally combined with a diuretic, and the use thereof
GB1578421A (en) Antiarrhythmic quinuclidine carboxylic acid xlidide
CS216902B2 (en) Method of making the new anilides of the aminoalkan acids
DE3314142A1 (en) Composition for the treatment of myocardial infarct
FR2544985A1 (en) Medicament based on a phenothiazine derivative for the treatment of myocardial infarction